NYSE:ZTSPharmaceuticals
How Lenivia’s Long-Acting Canine OA Launch At Zoetis (ZTS) Has Changed Its Investment Story
Zoetis has recently launched Lenivia (izenivetmab injection) in Canada and EU member states, a long-acting monoclonal antibody that provides up to three months of osteoarthritis pain management for dogs via a single subcutaneous injection, following nine-month European field studies showing sustained pain reduction from as early as Day 7.
This launch expands Zoetis’ osteoarthritis pain portfolio with a novel NGF-targeting therapy that offers extended relief and potentially better treatment...